Legend Biotech Stock

Legend Biotech Forward P/E

The Forward P/E Ratio of Legend Biotech (LEGN) as of Aug 15, 2026 is -10.94. In the previous year, Forward P/E Ratio was -18.34 — a change of -40.36% (higher).

Forward P/E

-10.94

YoY

-40.36%

Last updated:

Forward P/E Ratio of Legend Biotech is 2026 -10.94 . Forward P/E Ratio of Legend Biotech was 2025 -18.34 . It decreases by -40.36% higher compared to the previous year.
Access this data via the Eulerpool API

Legend Biotech Stock analysis

What does Legend Biotech do? Legend Biotech Corp is a leading biopharmaceutical company specializing in the discovery and development of innovative cell therapies for the treatment of serious diseases such as cancer. The company was founded in 2015 as a subsidiary of Genscript Biotech Corp and is headquartered in Somerset, New Jersey, USA. Additionally, the company also operates locations in China and Europe. Legend Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Legend Biotech stock

Forward P/E Ratio of Legend Biotech is -10.94 in 2026.

Forward P/E Ratio of Legend Biotech changed from -18.34 to -10.94, representing a -40.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Legend Biotech since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Legend Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Legend Biotech

All Key Metrics — Legend Biotech